Research programme: collagen formation inhibitors - FibroGen
Latest Information Update: 23 Mar 2007
At a glance
- Originator FibroGen
- Class Small molecules
- Mechanism of Action Bone morphogenetic protein receptor antagonists; Collagen inhibitors; Mixed function oxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Fibrosis
Most Recent Events
- 15 Aug 2002 This programme is still in active development
- 10 Sep 1999 Preclinical development for Fibrosis in USA (unspecified route)